AI stock discovery built on SEC filings with daily catalysts and plain-English summaries
Stage
Not given
Not given
Founded
Not given
Not given
Based in
Not given
ES
Pricing model
Freemium
Freemium
Pricing
Free plan with 6 daily signals (4 per day drawn randomly: 1 per method in Europe and 2 in US), limited access; Starter €9.99/month with all signals, conviction scores, and 15 markets; Professional €24.99/month with full signal analysis and unlimited alerts. Both paid plans include a 7-day free trial
Discovery tool: Free. API: Free (100 daily calls, attribution required); Builder €35.09/month or €350.90/year (EU prices incl. VAT); Pro €119.79/month or €1,197.90/year (EU prices incl. VAT).
Key features
1,700 stocks analyzed daily across 15 global markets
Bounce strategy targeting +3% in ~10 sessions
Impulse strategy targeting +10% over weeks
Conviction Score from 0 to 100 for each signal
Machine learning model analyzing 21 technical indicators
Quality, Value, Technical and Dividend stock rankings
Portfolio tracking with alerts and exit notifications
Daily data updates after market close
Public record of all closed signals with win/loss history
Five-perspective scoring system (Fundamentals, Value, News flow, Momentum, Safety)
Discovery Gap measurement showing progress vs. market attention
Material 8-K event classification using language models
Monthly point-in-time snapshots never restated
Stock research API with JSON output
Company timeline of material events from filings
End-of-day market data integration
Filing alerts and company follow functionality
What makes it different
Public scoreboard tracking US Bounce signals with conviction 86+ against S&P 500
Free daily signals drawn randomly (not cherry-picked) viewable without account
All closed trades publicly archived with no look-ahead bias
Historical win rate and past trade count shown for each signal
Transparent methodology: all five scoring perspectives shown with sources and evidence
Public record of all calls, including mistakes, never restated monthly
Research, not investment advice or recommendations